Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku, Torii to Invest in New Biotech Funds
July 2, 2020
- Tolerability of Telomelysin for HCC Confirmed in PI: Oncolys
July 2, 2020
- Eisai’s Eritoran to Enter Clinical Study for COVID-19 on Global Platform
July 2, 2020
- Towa Comarkets Celltrion’s Remicade Biosimilar in Japan
July 2, 2020
- Aspen Japan to Take Over Anti-Anxiety Med Lexotan
July 2, 2020
- AstraZeneca Taps Celgene Exec as New R&D Head
July 2, 2020
- 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
- Chugai Files Polatuzumab Vedotin for DLBCL in Japan
July 1, 2020
- Otsuka, Axcelead Link Up for Drug Discovery in CNS Field
July 1, 2020
- Nichi-Iko to Suspend Supply of Olmesartan OD Tab. 20 mg as COVID-19 Cripples API Procurement
July 1, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
- Sanofi Launches Japan’s 1st Humalog Biosimilar
June 30, 2020
- EU Advisory Panel Snubs Daiichi Sankyo Cancer Med Pexidartinib
June 30, 2020
- Takeda to See US$200 Million Operating Loss Tied to Novartis' EU Xiidra Withdrawal
June 30, 2020
- Mitsubishi Tanabe Files Inebilizumab in Japan for NMOSD
June 29, 2020
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…